Congenital Heart Innovation Report


Congenital Heart Center 2020 Innovation Report

Innovation at a Glance

  • Leaders in the care of babies born with a single ventricle including the creation of a patient-specific treatment algorithm to determine the first of three reconstructive surgeries (Norwood, Hybrid Stage I, or primary transplant) and transitional care from infancy to childhood, adolescence, and early adulthood
  • Expanding the use of 3D pre-procedure planning models to guide surgery and interventional procedures in children born with complex heart lesions, including ventricular assist device placement planning
  • Establishing the Center for Single Ventricle Care in 2014
  • Using an algorithm to differentiate whether to use the Ross or Ozaki aortic valve repair in children and adolescents, and removing the diseased aortic valve leaflets to create a new aortic valve with the pericardium in the Ozaki procedure
  • Expertise performing the hybrid approach for hypoplastic left heart syndrome, and one of a few centers in the U.S. to establish a formal pediatric hybrid program
  • Using a valved right ventricle to pulmonary artery (RV-PA) conduit for the Norwood-Sano procedure, resulting in better cardiac function during the perioperative period
  • Leaders in treating low-birthweight infants that require early surgical or transcatheter interventions including those with early complicated conditions involving either a ventricular septal defect or aortic arch anomalies
  • One of only a few institutions in the world to perform comprehensive multidisciplinary heart valve repair and replacement, including the latest percutaneous interventions, for children and adults with congenital malformations
  • First center in New York State to implant a transcatheter pulmonary valve in a native right ventricular outflow tract using the Alterra Adaptive Prestent
  • The first center in Manhattan to perform percutaneous patent ductus arteriosus closure in premature infants
  • Pioneers in the initial and ongoing development of transcatheter valve placement for congenital heart disease
  • Developing and refining pediatric interventional procedures as treatment for an increasing number of CHDs
  • Establishing the first cardiac ICU in the nation exclusively dedicated to the care of newborn infants with congenital heart disease
  • Advancing predictive monitoring as an alternative approach to assessing hemodynamic status of infants in the NICU to optimize end-organ tissue oxygenation and decrease morbidity and mortality
  • Demonstrating that whole-exome sequencing can serve as a valuable addition to standard prenatal genetic tests, with the potential to improve perinatal care for infants with genetic conditions
  • Developing a fetal cardiac intervention program, including fetal aortic and pulmonary balloon valvuloplasty as well as stenting of the interatrial septum for a subset of hypoplastic left heart fetuses with intact atrial septum
  • Implanting a Berlin heart as a bridge to transplant in the youngest patient ever to receive one – an infant only 2 days old
  • One of the first centers in the U.S. to implant the Jarvik 2015 VAD into a toddler as part of the PumpKIN clinical trial
  • Expertise in heart-lung transplantation for patients with single-lung physiology
  • Expertise in managing highly sensitized pediatric heart transplant patients
  • Developing the reversed valved Potts shunt, a novel surgery that alleviates strain on the right side of the heart, as a palliative bridge for pediatric patients with end-stage pulmonary hypertension
  • At the forefront of examining the impact of heart failure on adult congenital heart disease and helping to guide a national effort to improve patient outcomes through funded research and team-based clinical care